MedWatch

Novo Nordisk enters research collaboration with Flagship Pioneering

The venture capital firm brings its portfolio of life science firms to the table, while Novo Nordisk has funding at the ready for any research program that might stem from the partnership.

Photo: Stine Tidsvilde

Novo Nordisk and Flagship Pioneering, a life science venture capital firm based in the US, have struck a deal concerning the latter’s life science portfolio of firms, a joint press release has announced.

The portfolio, which Flagship describes as a ”bioplatform,” consists of 41 companies and will be leveraged to create research programs within cardiometabolic and rare diseases.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs